# Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg

> **NCT06719986** · PHASE1 · COMPLETED · sponsor: **Purdue Pharma LP** · enrollment: 24 (actual)

## Conditions studied

- Opioid Overdose

## Interventions

- **DRUG:** Nalmefene HCl injection
- **DRUG:** Naloxone HCl intranasal

## Key facts

- **NCT ID:** NCT06719986
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-03
- **Primary completion:** 2022-12-23
- **Final completion:** 2022-12-23
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06719986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06719986, "Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06719986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*